Citations

Showing 10 of 108104 citations.

Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
Sendi, Parham , Thierstein, Marc, Widmer, Nadja , Bosombo, Flora Babongo, Büchi, Annina Elisabeth , Güntensperger, Dominik , Tinguely, Caroline , Gahl, Brigitta , Heg, Dik , Theel, Elitza S. , Berbari, Elie F. , Niederhauser, Christoph , study, for the PoliCOV‐19, Berbari, Elie, Gahl, Brigitta , Büchi, Annina Elisabeth , Sendi, Parham , Blum, Manuel R. , Baldan, Rossella , Endimiani, Andrea , Gowland, Peter , study, for the PoliCOV‐19

Mayo Clinic

Immunity, Inflammation and Disease | June 6, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/iid3.640 | PMID 35759237 Get It

AbstractIntroductionTo assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign.MethodsThe cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires.ResultsThe mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose.ConclusionThese data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals.
Sinonasal Mucosal Melanoma: Role of Tumor Proliferative Indices and Pathological Factors in Survival
Guo, Ruifeng , Jenkins, Sarah M. , Johnson, Brian J. , Reed, Katelyn A. , Kroneman, Trynda, Reed, Katelyn, Choby, Garret , Johnson, Brian Jake , Guo, Ruifeng , Choby, Garret

Mayo Clinic

The Laryngoscope | June 6, 2022 | Volume: 132 | Issue: 12 | Pages: 2350-2358

10.1002/lary.30240 | PMID 35661370 Get It

Objective The objective of this study is to determine the association of proliferation indices and pathologic biomarkers on overall and recurrence/metastasis‐free survival (OS and RMFS) in patients with sinonasal mucosal melanoma (SNMM) and to assess the genetic mutational landscape of SNMM. Methods This is a retrospective cohort study of 45 SNMM patients without neoadjuvant therapy who underwent surgical therapy with curative intent and had tumor tissue available for histopathologic review, molecular analysis, and genetic mutational assessment. The OS and RMFS were assessed for associations with numerous tumor and patient‐related factors. Results Among proliferative indices, higher Ki67 and mitotic rates were associated with worsened OS and RMFS (Ki67: p = 0.0007 and p < 0.0001; mitotic rate: p = 0.005 and p = 0.0009, respectively). The presence of brisk tumor‐infiltrating lymphocytes (TILs) was associated with improved RMFS ( p = 0.007) and the presence of lymphovascular invasion was associated with worsened OS and RMFS ( p = 0.02 and p = 0.04, respectively). Patients with amelanotic tumors were more likely to have higher T‐stage ( p = 0.046), less likely to have brisk TILs ( p = 0.02) and had worsened RMFS ( p = 0.03). Patients on immunotherapy with tumor Ki67 < 40% had better 3‐year OS compared to those with higher Ki67 index ( p = 0.004). Actionable genetic mutations such as BRAF V600E are rare and present in only 1 of 20 patients tested. Conclusion In SNMM patients, pathologic and proliferation markers such as Ki67, mitotic rate and brisk TILs are associated with survival and may be considered in future staging systems. Clinical response to immunotherapy appears to correlate with the Ki67 index. Given the distinct genetic profile of SNMM, targeted therapies against the MAPK kinase pathway have limited utility. Level of Evidence 3 Laryngoscope , 132:2350–2358, 2022
Tumor protein D52 ( TPD52 ) affects cancer cell metabolism by negatively regulating AMPK
Chen, Yali , Peng, Changmin , Tan, Wei , Yu, Jia , Zayas, Jacqueline , Peng, Yihan , Pei, Huadong , Wang, Liewei , Pei, Huadong , Lou, Zhenkun

Mayo Clinic

Cancer Medicine | June 6, 2022 | Volume: 12 | Issue: 1 | Pages: 488-499

10.1002/cam4.4911 | PMID 35666017 Get It

Abstract Background The AMP‐activated protein kinase (AMPK) is a central regulator of energy homeostasis, with deregulation leading to cancer and other diseases. However, how this pathway is dysregulated in cancer has not been well clarified. Methods Using a tandem affinity purification/mass‐spec technique and biochemical analyses, we identified tumor protein D52 (TPD52) as an AMPKα‐interacting molecule. To explore the biological effects of TPD52 in cancers, we conducted biochemical and metabolic assays in vitro and in vivo with cancer cells and TPD52 transgenic mice. Finally, we assessed the clinical significance of TPD52 expression in breast cancer patients using bioinformatics techniques. Results TPD52, initially identified to be overexpressed in many human cancers, was found to form a stable complex with AMPK in cancer cells. TPD52 directly interacts with AMPKα and inhibits AMPKα kinase activity in vitro and in vivo. In TPD52 transgenic mice, overexpression of TPD52 leads to AMPK inhibition and multiple metabolic defects. Clinically, high TPD52 expression predicts poor survival of breast cancer patients. Conclusion The findings revealed that TPD52 is a novel regulator of energy stress‐induced AMPK activation and cell metabolism. These results shed new light on AMPK regulation and understanding of the etiology of cancers with TPD52 overexpression.
Young adults who improve performance during dual-task walking show more flexible reallocation of cognitive resources: a mobile brain-body imaging (MoBI) study
Patelaki, Eleni , Foxe, John J. , Mazurek, Kevin A. , Freedman, Edward G. , Mazurek, Kevin A

Mayo Clinic

Cerebral Cortex | June 6, 2022 | Volume: 33 | Issue: 6 | Pages: 2573-2592

10.1093/cercor/bhac227 | PMID 35661873 Get It

Abstract Introduction In young adults, pairing a cognitive task with walking can have different effects on gait and cognitive task performance. In some cases, performance clearly declines whereas in others compensatory mechanisms maintain performance. This study investigates the preliminary finding of behavioral improvement in Go/NoGo response inhibition task performance during walking compared with sitting, which was observed at the piloting stage. Materials and Methods Mobile brain/body imaging (MoBI) was used to record electroencephalographic (EEG) activity, 3-dimensional (3D) gait kinematics and behavioral responses in the cognitive task, during sitting or walking on a treadmill. Results In a cohort of 26 young adults, 14 participants improved in measures of cognitive task performance while walking compared with sitting. These participants exhibited walking-related EEG amplitude reductions over frontal scalp regions during key stages of inhibitory control (conflict monitoring, control implementation, and pre-motor stages), accompanied by reduced stride-to-stride variability and faster responses to stimuli compared with those who did not improve. In contrast, 12 participants who did not improve exhibited no EEG amplitude differences across physical condition. Discussion The neural activity changes associated with performance improvement during dual tasking hold promise as cognitive flexibility markers that can potentially help assess cognitive decline in aging and neurodegeneration.
Early combination therapy with immunoglobulin and steroids is associated with shorter ICU length of stay in Multisystem Inflammatory Syndrome in Children (MIS‐C) associated with COVID‐19: A retrospective cohort analysis fro
Harthan, Aaron A. , Nadiger, Meghana , McGarvey, Jeremy , Hanson, Keith , Gharpure, Varsha , Miller, Aaron S., Reikoff, Ronald A., Kumar, Vishakha K. , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry Investigator, Danesh, Valerie , Gharpure, Varsha P , Bjornstad, Erica C. , Chiotos, Kathleen , Gajic, Ognjen , Walkey, Allan J. , Kashyap, Rahul , Tripathi, Sandeep , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry Investigator

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | June 6, 2022 | Volume: 42 | Issue: 7 | Pages: 529-539

10.1002/phar.2709 | PMID 35661394 Get It

AbstractObjectivesSuggested therapeutic options for Multisystem Inflammatory Syndrome in Children (MIS‐C) include intravenous immunoglobulins (IVIG) and steroids. Prior studies have shown the benefit of combination therapy with both agents on fever control or the resolution of organ dysfunction. The primary objective of this study was to analyze the impact of IVIG and steroids on hospital and ICU length of stay (LOS) in patients with MIS‐C associated with Coronavirus Disease 2019 (COVID‐19).Study DesignThis was a retrospective study on 356 hospitalized patients with MIS‐C from March 2020 to September 2021 (28 sites in the United States) in the Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS) COVID‐19 Registry. The effect of IVIG and steroids initiated in the first 2 days of admission, alone or in combination, on LOS was analyzed. Adjustment for confounders was made by multivariable mixed regression with a random intercept for the site.ResultsThe median age of the study population was 8.8 (Interquartile range (IQR) 4.0, 13) years. 247/356 (69%) patients required intensive care unit (ICU) admission during hospitalization. Overall hospital mortality was 2% (7/356). Of the total patients, 153 (43%) received IVIG and steroids, 33 (9%) received IVIG only, 43 (12%) received steroids only, and 127 (36%) received neither within 2 days of admission. After adjustment of confounders, only combination therapy showed a significant decrease of ICU LOS by 1.6 days compared to no therapy (exponentiated coefficient 0.71 [95% confidence interval 0.51, 0.97, p = 0.03]). No significant difference was observed in hospital LOS or the secondary outcome variable of the normalization of inflammatory mediators by Day 3.ConclusionsCombination therapy with IVIG and steroids initiated in the first 2 days of admission favorably impacts ICU but not the overall hospital LOS in children with MIS‐C.
The reemergence of monkeypox as a new potential health challenge: A critical review
Afshar, Zeinab Mohseni , Rostami, Hossein Nazari, Hosseinzadeh, Rezvan , Janbakhsh, Alireza , Pirzaman, Ali Tavakoli , Barary, Mohammad , Ebrahimpour, Soheil , Barary, Mohammad , Tavakoli Pirzaman, Ali , Babazadeh, Arefeh , Aryanian, Zeinab , Sio, Terence T.

Mayo Clinic

No container title available | June 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165446104.43472483/v1 Get It

Human monkeypox is a zoonotic Orthopoxvirus resembling smallpox in clinical course, making it difficult to distinguish it from smallpox and varicella. Laboratory diagnostics are critical components of illness identification and surveillance, and novel tests are required for more precise and quick diagnosis. The majority of human infections occur in Central Africa, where monitoring in remote regions with little infrastructure is challenging but may be performed using evidence-based methods and teaching materials that educate public health personnel on the fundamental principles of this infection. New medications and vaccinations showed promising results for the treatment and prevention of the disease, but more studies are required to show their efficacy in the actual endemic settings. Thus, more studies are needed on the virus's epidemiology, ecology, and biology in endemic locations to better understand and prevent human infections. This review discussed the etiology, epidemiology, and clinical course of the monkeypox and indicated diagnostic and treatment approaches for this disease.
Coating Bioactive Microcapsules with Tannic Acid Enhances the Phenotype of the Encapsulated Pluripotent Stem Cells
Gwon, Kihak , Hong, Hye Jin , Baskaran, Harihara , Calvo-Lozano, Olalla , Gonzalez‐Suarez, Alan M. , Park, Kyungtae , Lechuga, Laura M. , Hong, Jinkee , Revzin, Alexander , Choi, Daheui , Calvo-Lozano, Olalla , Gonzalez-Suarez, Alan M, Lechuga, Laura M , Hong, Jinkee , Revzin, Alexander , Gwon, Kihak , Gonzalez-Suarez, Alan M , Hoyos‐Vega, José M. de , Stybayeva, Gulnaz

Mayo Clinic

ACS Applied Materials & Interfaces | June 4, 2022 | Volume: 14 | Issue: 23 | Pages: 27274-27286

10.1021/acsami.2c06783 | PMID 35658394 Get It

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, Thomas G. , Usmani, Saad Z. , Berdeja, Jesús G. , Agha, Mounzer , Cohen, Adam D. , Hari, Parameswaran , Avigan, David , Deol, Abhinav , Htut, Myo , Lesokhin, Alexander M. , Munshi, Nikhil C. , O’Donnell, Elizabeth , Stewart, A. Keith , Schecter, Jordan M. , Goldberg, Jenna D., Jackson, Carolyn C. , Yeh, Tzu‐Min, Banerjee, Arnob , Allred, Alicia J., Zudaire, Enrique, Deraedt, William , Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida , Lin, Yi , Jakubowiak, Andrzej , Lin, Yi , Jagannath, Sundar , Lesokhin, Alexander M , Cohen, Adam D , Hari, Parameswaran , Berdeja, Jesús G , Usmani, Saad , Goldberg, Jenna D., Madduri, Deepu , Jakubowiak, Andrzej , Jagannath, Sundar

Mayo Clinic

Journal of Clinical Oncology | June 4, 2022 | Volume: 41 | Issue: 6 | Pages: 1265-1274

10.1200/jco.22.00842 | PMID 35658469 Get It

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. Here, we present updated results 2 years after last patient in (median follow-up [MFU] approximately 28 months), including analyses of high-risk patient subgroups. METHODS Eligible patients had relapsed/refractory multiple myeloma, had received ≥ 3 prior lines of therapy or were double refractory to a proteasome inhibitor and immunomodulatory drug and had received prior proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy. Patients received a single cilta-cel infusion 5-7 days after lymphodepletion. Responses were assessed by an independent review committee. RESULTS At a MFU of 27.7 months (N = 97), the overall response rate was 97.9% (95% CI, 92.7 to 99.7); 82.5% (95% CI, 73.4 to 89.4) of patients achieved a stringent complete response. Median duration of response was not estimable. Median progression-free survival (PFS) and overall survival (OS) were not reached; 27-month PFS and OS rates were 54.9% (95% CI, 44.0 to 64.6) and 70.4% (95% CI, 60.1 to 78.6), respectively. Overall response rates were high across all subgroups (95.1%-100%). Duration of response, PFS, and/or OS were shorter in patients with high-risk cytogenetics, International Staging System stage III, high tumor burden, or plasmacytomas. The safety profile was manageable with no new cilta-cel–related cytokine release syndrome and one new case of parkinsonism (day 914 after cilta-cel) since the last report. CONCLUSION At approximately 28 months MFU, patients treated with cilta-cel maintained deep and durable responses, observed in both standard and high-risk subgroups. The risk/benefit profile of cilta-cel remained favorable with longer follow-up.
A rare cause of infantile achalasia: GMPPA‐congenital disorder of glycosylation with two novel compound heterozygous variants
Geiculescu, Irina , Dranove, Jason E. , Cosper, Graham H., Edmondson, Andrew C. , Morava‐Kozicz, Eva, Carter, Lauren B. , Edmondson, Andrew C

Mayo Clinic

American Journal of Medical Genetics Part A | June 4, 2022 | Volume: 188 | Issue: 8 | Pages: 2438-2442

10.1002/ajmg.a.62859 | PMID 35665995 Get It

AbstractAchalasia is rare in the pediatric population and should prompt clinicians to consider genetic disorders associated with this condition. While AAA syndrome (also known as Allgrove or Triple A syndrome) is commonly considered, GMPPA‐congenital disorder of glycosylation (CDG) should also be in the differential diagnosis. We report a 9‐month‐old female born to nonconsanguineous parents with achalasia and alacrima found to have two novel compound heterozygous variants in the GMPPA gene associated with GMPPA‐CDG. This rare disorder is commonly associated with developmental delay and intellectual disability. We discuss management of this disorder including the importance of confirming a genetic diagnosis and summarize reported cases.